SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-3MEF - Registration statement to add securities to prior Form F-3 registration [Rule 462(b)]:
SEC Accession No. 0001213900-21-007889
Filing Date
2021-02-09
Accepted
2021-02-09 21:40:00
Documents
7
Effectiveness Date
2021-02-09

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea135073-f3mef_enlivextherap.htm F-3MEF 50291
2 OPINION OF YIGAL ARNON & CO. ea135073ex5-1_enlivextherap.htm EX-5.1 46903
3 OPINION OF GREENBERG TRAURIG, P.A ea135073ex5-2_enlivextherap.htm EX-5.2 19522
4 CONSENT OF YAREL + PARTNERS, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING ea135073ex23-1_enlivextherap.htm EX-23.1 2488
5 GRAPHIC ex5-1_001.jpg GRAPHIC 66852
6 GRAPHIC ex23-1_001.jpg GRAPHIC 7265
7 GRAPHIC ex23-1_002.jpg GRAPHIC 13069
  Complete submission text file 0001213900-21-007889.txt   240966
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-3MEF | Act: 33 | File No.: 333-252926 | Film No.: 21608940
SIC: 2834 Pharmaceutical Preparations